Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice

Psychotherapy and Psychosomatics
Maurizio Fava, A John Rush

Abstract

Most patients with major depressive disorder (MDD) do not reach symptom remission. These patients with residual symptoms have worse function and worse prognosis than those who remit. Several augmentation and combination treatments are used to either increase the chances of achieving remission or to eliminate/minimize residual depressive symptoms. Evidence for these pharmacological approaches rests primarily on open, uncontrolled studies, and there are clearly not enough controlled studies. Clinicians should carefully weigh these different treatment options to increase their patients' chances of achieving and sustaining remission from depression. This paper will review the pertinent studies and will propose a novel approach to improve practice involving the use of augmentation or combination strategies at the outset of initial treatment to primarily enhance the chances of remission through synergy and/or a broader spectrum of action. This novel approach could potentially enhance retention and/or increase remission rates since the lack of response with antidepressant monotherapy may lead many depressed patients with little or no benefit to drop out of treatment, precluding the subsequent use of augmentation or combination strateg...Continue Reading

References

Nov 1, 1979·Psychopharmacology·C de MontignyL Annable
Aug 15, 1992·Biological Psychiatry·J M De la Fuente, J Mendlewicz
Jul 1, 1992·Pharmacopsychiatry·L LauritzenP Bech
Jan 1, 1991·International Clinical Psychopharmacology·A Metz, R I Shader
Apr 1, 1991·Journal of Clinical Psychopharmacology·J FawcettM R Schaff
Jun 1, 1986·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·D KantorM Krenn
Apr 1, 1988·Journal of Clinical Psychopharmacology·P M ZuskyD R Gastfriend
Jun 1, 1971·The American Journal of Psychiatry·R N WhartonS Malitz
Oct 1, 1995·The American Journal of Psychiatry·A A NierenbergM Fava
Feb 1, 1995·Journal of Clinical Psychopharmacology·J A BodkinJ O Cole
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·C L KatonaM M Robertson
Jul 1, 1994·The American Journal of Psychiatry·A A NierenbergM Rosenthal
May 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·G Stein, M Bernadt
Jun 1, 1993·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·N R VarneyR J Roberts
Nov 1, 1995·Psychological Medicine·R RamanaP G Surtees
Nov 1, 1995·Psychological Medicine·E S PaykelA Barocka
Mar 1, 1996·International Clinical Psychopharmacology·K OtaniK Sugawara
Sep 1, 1996·Archives of General Psychiatry·F M QuitkinD F Klein
Sep 1, 1996·Archives of General Psychiatry·R AronsonC D Naylor
Jun 1, 1996·The Psychiatric Clinics of North America·M Fava, K G Davidson
Apr 1, 1997·The Journal of Clinical Psychiatry·J A BodkinR J Baldessarini
Dec 31, 1997·The Journal of Clinical Psychiatry·F A MorenoP L Delgado
Dec 31, 1997·Journal of Clinical Psychopharmacology·R ZanardiJ Perez
Jun 6, 1998·Depression and Anxiety·P S MasandJ F Tanquary
Sep 15, 1998·Archives of General Psychiatry·G A FavaP Belluardo
Dec 24, 1998·Journal of Clinical Psychopharmacology·E C Dimitriou, C E Dimitriou
Mar 13, 1999·The Journal of Clinical Psychiatry·L L CarpenterL H Price
Apr 30, 1999·The Journal of Clinical Psychiatry·A A NierenbergM Fava
Apr 30, 1999·The Journal of Clinical Psychiatry·R B Ostroff, J C Nelson

❮ Previous
Next ❯

Citations

Nov 17, 2009·Current Psychiatry Reports·Rachel Manber, Andrea S Chambers
May 3, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Khatereh SepanjniaShahin Akhondzadeh
Jun 14, 2012·Psychotherapy Research : Journal of the Society for Psychotherapy Research·Gry StålsettJon T Monsen
Aug 16, 2008·International Clinical Psychopharmacology·Amir GarakaniJack Hirschowitz
Nov 10, 2009·International Clinical Psychopharmacology·George I PapakostasMaurizio Fava
Oct 1, 2006·Acta Neuropsychiatrica·Robert D Goldney, Marcus A Bain
Jun 1, 2007·International Journal of Clinical Practice·C RafanelliN Sonino
Aug 19, 2007·Psychotherapy and Psychosomatics·Giovanni A FavaSilvana Grandi
Oct 6, 2007·Psychotherapy and Psychosomatics·Chantal HenryEduard Vieta
Dec 17, 2009·The Australian and New Zealand Journal of Psychiatry·Gin S MalhiMichael Berk
Aug 3, 2010·Pharmaceuticals·Joshua A Israel
Aug 24, 2007·Expert Opinion on Investigational Drugs·Russell T Joffe
Aug 28, 2010·Expert Opinion on Investigational Drugs·Arun V RavindranGebrehiwot Abraham
Aug 9, 2011·Comprehensive Psychiatry·I-Chia ChienPesus Chou
Dec 9, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shinichiro NakajimaHiroyuki Uchida
Jul 21, 2009·Journal of Psychiatric Research·Jerome SarrisGerard Byrne
May 25, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Marcelo T Berlim, Gustavo Turecki
Mar 14, 2016·La Presse médicale·Jérôme HoltzmannEmmanuel Haffen
Aug 8, 2009·Pharmacoepidemiology and Drug Safety·Stephen R WisniewskiAndrei Pikalov
Jun 23, 2009·Bipolar Disorders·Samuel GershonGin S Malhi
Feb 1, 2007·Early Intervention in Psychiatry·Giovanni A Fava, Eliana Tossani
Sep 19, 2007·Journal of Clinical Pharmacy and Therapeutics·A F CarvalhoM C O Lima
Oct 7, 2008·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Giovanni A FavaSteven L Dubovsky
Mar 22, 2014·Journal of Pineal Research·Gerardo Ramírez-RodríguezErika Estrada-Camarena
Oct 9, 2007·Biological Psychiatry·George I PapakostasMichael E Thase
Apr 10, 2015·Annals of the New York Academy of Sciences·Marc S Lener, Dan V Iosifescu
Jun 1, 2011·Annals of Medicine·Eduard Vieta, Francesc Colom
Apr 28, 2011·Neuron·Martin A KohliElisabeth B Binder
Nov 22, 2011·Journal of Ethnopharmacology·M Martínez-VázquezG Heinze
Dec 17, 2014·Journal of Affective Disorders·Sharon C SungUNKNOWN COMED Study Team
Nov 10, 2011·São Paulo Medical Journal = Revista Paulista De Medicina·Anna Lucia Spear KingAntonio Egidio Nardi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2022 Meta ULC. All rights reserved